|
|
Application study of high flux hemodialysis combined with hemoperfusion in the treatment of uremia |
RUAN Chun-yun LIU Sheng-shan |
Department of Nephrology, the Third Hospital of Nanchang, Jiangxi Province, Nanchang 330000, China |
|
|
Abstract Objective To explore the application of high flux hemodialysis combined with hemoperfusion in the treatment of uremia. Methods A total of 80 patients with uremia admitted to the Department of Nephrology, the Third Hospital of Nanchang from April 2020 to July 2020 were selected as the research objects and divided into the control group (40 cases) and the observation group (40 cases) according to the random sampling. The control group was given high flux hemodialysis treatment, and the observation group was given hemoperfusion treatment on the basis of the control group, patients of both groups were treated continuously for 12 weeks. The changes of toxin clearance index, inflammatory factors and immune function before treatment and 12 weeks after treatment were compared between the two groups. Results After 12 weeks of treatment, the serum creatinine (Scr), blood urea nitrogen (BUN), parathyroid hormone(Pth), β2-microglobulin (β2-MG) and serum C-reactive protein ( CRP), serum interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) levels were lower than those before treatment in this group, and the observation group was lower than the control group; while serum immunoglobulin A (IgA) and immunoglobulin G ( IgG), immunoglobulin M (IgM) levels and complement C3, C4 levels were higher than those before treatment in this group, and the observation group was higher than the control group, the differences were statistically significant (P<0.05). Conclusion High-flux hemodialysis combined with hemoperfusion can effectively remove various toxins in uremic patients, thereby reducing inflammatory factors, improving the immunity of uremic patients, and promoting the improvement of their condition.
|
Received: 12 January 2021
|
|
|
|
[1] |
许绯.以神经系统症状为突出表现的尿毒症患者的临床分析[J].中国医药导刊,2015,17(8):44-46.
|
[2] |
张文阁,李强,刘翠,等.血液透析联合不同时机的血液灌流对尿毒症患者中分子毒素清除效果的探讨[J].医学研究杂志,2017,46(11):101-105.
|
[3] |
曾洁纯,刘晓冰,吕伟权.血液透析联合血液灌流在慢性肾衰竭治疗中的应用价值体会[J].国际医药卫生导报,2020,26(9):1276-1278.
|
[4] |
叶任高,陆再英.内科学[M].北京:人民卫生出版社,2004:523-528.
|
[5] |
姜鹏飞,李秋萍,杨洋.尿毒症血液透析患者营养不良的原因及营养护理干预[J].中国全科医学,2018,21(1):434-436.
|
[6] |
范勇霞.高通量血液透析联合血液灌流治疗尿毒症顽固性高血压的疗效[J].国际移植与血液净化杂志,2019,17(3):23-25.
|
[7] |
刘崇文,夏秀花,朱金庆.血液透析联合血液灌流治疗尿毒症32 例分析[J].中国医师杂志,2012,(1):83-85.
|
[8] |
张少鑫.血液透析联合血液灌流治疗对尿毒症患者β2-微球蛋白的清除效果研究[J].中国临床医生杂志,2017,10(37):34-37.
|
[9] |
陈昕,张莹.血液透析联合血液灌流对尿毒症患者毒素清除率、炎性因子、钙磷代谢及免疫功能的影响[J].陕西医学杂志,2019,48(6):770-773.
|
[10] |
刘秀艳.尿毒清颗粒联合缬沙坦对尿毒症微炎症状态影响及肾功能保护研究[J].河北医药,2017,39(13):1986-1988.
|
[11] |
王润蕾,齐永灵,杨眉,等.血液透析联合血液灌流对尿毒症患者毒素清除率及颈动脉内膜的影响[J].海南医学院学报,2017,12(187):43-45.
|
[12] |
穆立芹,王静,李明明,等.探讨尿毒症血液透析患者透析前后免疫指标及IL-6、CRP、IL-8、TNF-α 的变化[J].现代免疫学,2017,37(6):489-493.
|
[13] |
牛世慧,刘莉,储昭霞.血液透析对尿毒症患者临床疗效及炎症因子影响研究[J].临床军医杂志,2018,46(11):1373-1374
|
[14] |
王青,白寿军,杨明正,等.高通量血液透析联合复方α酮酸治疗尿毒症疗效及对患者机体免疫功能的影响[J].现代中西医结合杂志,2018,27(25):2832-2835.
|
[15] |
陈艳来.血清IgA、IgG、IgM、补体C3及补体C4联合检测在诊断肾病综合征中的应用价值分析[J].当代医药论丛,2019,17(6):87-88.
|
[16] |
王军,袁纯辉,袁文,等.肾病综合征患儿外周血T 淋巴细胞亚群、免疫球蛋白、补体表达观察[J].山东医药,2019,59(6):79-81.
|
|
|
|